LY2857785 is a potent, reversible, and competitive ATP-competitive inhibitor targeting CDK7, CDK8, and CDK9 with IC50 values of 246 nM, 16 nM, and 11 nM, respectively. This small molecule is a valuable research tool for studying transcriptional regulation and cell cycle progression in both in vitro and in vivo cancer research models.